Cerebrovascular disease also known as stroke, is a condition caused by cerebral ischemia or haemorrhage. Ischemic events are further classified on the basis of occurrences of (in vertebrobasilar or carotid distribution) and duration of symptoms. Facial weakness, vertigo, dysphagia, diplopia, dysarthria, gait ataxia, hemisensory numbness, hemiparesis, limb dysmetria, cortical blindness, and bilateral weakness and numbness are some of the symptoms observed in the patients with ischemic stroke. Cerebrovascular disease can be treated by medications such as; antiplatelets, blood thinners, antihypertensives, and anti-diabetic medications. Bayer AS is in the process of developing rivaroxaban as a factor IXa inhibitors for the treatment of cerebrovascular disease. Boehringer Ingelheim GmbH is in the process of developing alteplase as a plasminogen activator for the treatment of the disease. Some of the companies having a pipeline of cerebrovascular disease include Bayer AG, NoNO Inc., F Hoffmann-La Roche AG and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.